chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Systemic: Dizziness / Lightheadness-Medium, Systemic: Exhaustion / Lethargy-Medium, Systemic: Flushed / Sweating-Medium, Systemic: Tingling (specify: facial area, extemities)-Medium, Additional Details: Was pale and sweating, had a significant other that drove him home from the store
"Moderna COVID-19 vaccine EUA" Patient received 0.5ml instead of 0.25ml of COVID booster vaccine.
Tenderness; Pain at the injection site; A spontaneous report  was received from a physician concerning his wife, a 71-year-old, female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced tenderness (Tenderness) and pain at the injection site (Vaccination site pain).     The patient's medical history was not provided. No relevant concomitant medications were provided.     On 29 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot: 039K20A) via unknown route for prophylaxis of COVID-19.  On 30 Dec 2020, the patient experienced tenderness and pain at the injection site. No treatment information was provided.   Action taken with mRNA-1273 in response to the event was not reported.   The outcome for the events, tenderness and pain at the injection site, were resolved on 01 Jan 2021.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This spontaneous report as received from a physician via an unspecified field representative on 30-OCT-2014 refers to four different patients of unknown age and gender. The field representative reported to brain from "CTT" that they were informed by a healthcare worker. Four prefilled syringes of RECOMBIVAX HIB injection 5/0.5 microgram/ml (dose, lot # unknown) which were discovered to be leaking from an unspecified location after administration to four different patients on an unknown date. Product quality complaint (PQC) filed. No adverse experiences were reported. All patients were anonymous.  The outcome of event was not provided. Additional information has been requested.
Pt recvd vax on 15MAY92, 21AUG92 & 12FEB93 & on 28FEB92, lab eval revealed that pt had a pos HBsAg; repeat testing in a different lab, on 25FEB92 & 1MAR92 indicated neg HBsAg & pos anti-HBs; 4MAR93 pt died following head trauma;
patient is pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE BEFORE PREGNANCY (patient is pregnant) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003B21A and 027A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 31-Jan-2022. On 24-Mar-2021, the patient experienced MATERNAL EXPOSURE BEFORE PREGNANCY (patient is pregnant). On 24-Mar-2021, MATERNAL EXPOSURE BEFORE PREGNANCY (patient is pregnant) had resolved.            No concomitant and treatment medication were provided The patient's last menstruation date was 26-Apr-2021. Company Comment: This case concerns a 29 year-old, female patient with no relevant medical history, with Maternal exposure before pregnancy and no associated adverse events reported. The patient received first dose of mRNA-1273 vaccine on 24 march and second dose on 21 april and her last menstrual period was reported on 26 april 2021. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This case concerns a 29 year-old, female patient with no relevant medical history, with Maternal exposure before pregnancy and no associated adverse events reported. The patient received first dose of mRNA-1273 vaccine on 24 march and second dose on 21 april and her last menstrual period was reported on 26 april 2021. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
After receiving Flu vaccine developed fever 101 then had two episodes of generalized tonic seizures.
She got the first Pfizer Vaccine on 7/23 and then she got COVID; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: not reported), via an unspecified route of administration on 23Jul2021 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On 02Aug2021, patient got COVID and and she got the antibody infusion on 03Aug2021, so did not recommended to wait 90 days past antibody infusion and to get a dose of COVID vaccine and she already got her first dose and then they did not recommend doing more than 42 for your second dose. The patient underwent lab tests and procedures which included COVID-19 test: positive on 02Aug2021. Outcome of the event was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Pt presented with COVID no hypoxia didn't require medication. Pt treated for Chf exacerbation and discharged home once stable.
The consumer did not report any side effects. No additional AE reported; received GARDASIL-9 by mistake and was not scheduled to receive the vaccine.; AE Onset Date/Date PQC First identified: 8/26/2021 / Expiration date: 4/28/2021; This spontaneous report has been received from a medical assistant referring to a patient of unknown age and gender. The patient's medical history, drug and allergy history, concurrent conditions, and concomitant medications were not reported.    On 26-AUG-2021, the patient was vaccinated with HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) 0.5 milliliter (ml) (route of administration, vaccine scheme, and anatomical site of vaccination were not reported). Lot number U008600 is an invalid lot number for PV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9), confirmed by lot verification team, expiration date reported as 28-APR-2021 (expired product administered).   It was reported that the patient was administered HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) by mistake and was not scheduled to receive the vaccine (product administration error). No additional adverse event (AE) reported.
MAJOR HEART PROBLEMS; This spontaneous report received from a consumer  concerned a 6 decade old male of unspecified race and ethnicity. The patient's height, and weight were not reported. The patient was perfectly healthy. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown and expiry: UNKNOWN) dose, start therapy date were not reported,1 total administered for prophylactic vaccination (dose number in series 1). The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced major heart problems and was hospitalized (date unspecified). Number of days of hospitalization was not reported. It was unknown if patient was discharged. As per the report, it was stated that "you are lucky, My husbands friend died 2 weeks after getting his second shot. My neighbor had hand tremors with the feeling of electricity going down her arms and my daughter's friend is in the hospital with major heart problems. He is 50 and was perfectly healthy. The docs told him that it is probably from the shot" The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of major heart problems was not reported. This report was serious (Hospitalization Caused / Prolonged). This case, from the same reporter is linked to 20211229554 and 20211229704.; Sender's Comments: 20211230043- COVID-19 VACCINE AD26.COV2.S-major heart problems. This event(s) is considered unassessable. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Approximately 2 weeks post vax the pt developed a varicella like rash which consisted of approximately 12 lesions that were scattered over the body. No other symptoms were present. Approximately 1 week after the pt recovered, she received the second dose of varicella vaccine live. No adverse reactions followed the second dose.
Symptoms within 7-9 days after injection. Swelling in upper left chest, neck, and clavicle area. Ear and throat soreness only on left side. Aching and numbness in left arm.  Decrease in symptoms after 6 days. no treatments or medications.
Child received Tdap & MENACTRA in left deltoid on 12/13/11. On 12/14/11 am child's arm started to swell with redness, hot to touch & induration of 14x10 cm. Man came in w/ child for assessment & was given symptom treatment instructions.
This spontaneous report was received from a physician assistant concerning an 18 years old female patient who on and unknown date was vaccinated with the first dose of RECOMBIVAX HB 5 mcg (route and lot # not provided) and on an unknown date received the second dose of RECOMBIVAX 5 mcg (route and lot # not provided). The physician assistant reported that on an unknown date, the patient was inadvertently vaccinated with 1 mcg of RECOMBIVAX HB (route and lot # not provided) instead of 5 mcg. This was the patient's third dose in the series. No adverse effects were reported. Additional information has been requested.
No adverse event; 2ND DOSE Dec 28 2022/ 3RD DOSE 28Feb2023; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2ND DOSE Dec 28 2022/ 3RD DOSE 28Feb2023) and NO ADVERSE EVENT (No adverse event) in a 9-month-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. AS1903B, AS1417B and AS1417B) for COVID-19 prophylaxis.     No Medical History information was reported.   On 28-Nov-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Dec-2022, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Feb-2023, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On 28-Feb-2023,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2ND DOSE Dec 28 2022/ 3RD DOSE 28Feb2023). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2ND DOSE Dec 28 2022/ 3RD DOSE 28Feb2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (2ND DOSE Dec 28 2022/ 3RD DOSE 28Feb2023).    No concomitant medications were reported. It was Unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  Patient was not immunocompromised. No treatment details were reported.
Fever, myalgias, headache, chills starting 4-5 hours after vaccine administration and continuing overnight
Extreme hot flashes; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL5302) via an unspecified route of administration on an unknown date in Jan2021 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EK5730) via an unspecified route of administration on an unknown date in Dec2020 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. On an unknown date in Jan2021, with the second dose, the patient experienced extreme hot flashes. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event hot flashes was not resolved at the time of this report.
Patient had several visits to the ED within 6 weeks of receiving COVID vaccination. She presented to the ED on 6/4/2021 for paranoid psychosis. She presented to the ED on 06/09/2021 and was subsequently hospitalized for amphetamine dependence.
I felt symptoms from taking chemotherapy due to having pancreas cancer. I just returned from a cruise with my family. Before we boarded the ship we had to take a COVID-19 test which was negative. After the cruise, I decided to test and the COVID-19 test was positive. I was the only one in my family that was positive. I contacted my oncologist because I was suppose to start chemotherapy back next week. I was prescribed Paxlovid to take for 5 days. My symptoms were like allergies with eyes watery and burning with a mild cough and runny nose that lasted 2 days.
Thigh swelling to knee. Greater day 3 no redness, normal gait. 5th DTaP. No fever. TX cool compresses. Follow up call swelling resolved 09/09/16.
Pt dizzy immediately after shot administration. c/o dizziness with any IM shots in the past.
This is a spontaneous report obtained from a contactable consumer. This 53 year old, male patient received single dose, on 15May2012 as a pneumonia preventive vaccine. Relevant medical history and concomitant medications were none. The patient experienced gastrointestinal cramping since 24May2012 (which was king of severe stomach cramping) and bronchitis like symptoms since 27May2012. Relevant laboratory data was none. The therapeutic measures included ADVIL (dose and frequency was unknown) for bronchitis like symptoms since an unknown date in May2012 and the patient also mentioned that he had taken unspecified OTC (dose and frequency was unknown) for gastrointestinal cramping on an unknown date in May2012. The patient had recovered from the events on an unknown date in 2012. Follow-up (03AUG2012) Follow-up attempts completed. No further information expected.
This spontaneous report as received from registered nurse refers to an unspecified patients of an unknown age and unknown gender. On an unknown dates in 2015 (reported as past week), the unspecified patients were vaccinated with improperly stored LIQUID PEDVAXHIB (Lot# K008877, expiry date: 24-FEB-2017 and Lot# K019700, expiry date: 16-JUL-2017) (dose, frequency and route were not reported). No adverse effects were reported. No product quality complaint (PQC) was reported for LIQUID PEDVAXHIB. This is one of the several reports from the same reporter. Additional information is not expected as the reporter did not wish to contact.
Left arm pain at site of injection, throbbing down the arm, burning sensation and heaviness.  Inability to raise arm and entire arm swollen. In addition to this on the first day of the adverse event flu like symptoms which lasted two days.  Arm pain continues as at day four since adverse event started
48 hours after the vaccine I started feeling flushed cheeks; vertigo; nausea; neuropathy; numbness in arms, hands and legs; headache; nerve pain; brain fog and fatigue. I was in bed for 3 weeks and I was out of work for 5 weeks off in October. My Immunologist believes it is a neurological disorder that is making my immune system attack my nervous system. My COVID antibody levels are 11,800 way higher then what they are supposed to be. This went on for a few weeks. I also wanted to add that my husband and daughter had RSV in late November which re-flared my immune system. Taking an additional 3 days off work as my condition has only improved slightly but is still ongoing. I was prescribed gabapentin which blocks the nervous system and a tapered dose of prednisone. I started my course of steroids last 12/20/2022.
pain in his left arm, predominately in his shoulder and the left side of chest.; pain in his left arm; pain in his left arm, predominately in his shoulder and the left side of chest.; This is a spontaneous report from a contactable consumer. This male consumer (patient) reported. A male patient with an unspecified age received second dose of BNT162b2 (COMIRNATY, formulation: solution for injection, Lot number: unknown) via unknown route of administration on 17Feb2021 as Dose 2,Single for COVID-19 immunization. The patient's medical history and concomitant medication were not reported. Historical vaccine included first dose of BNT162b2 (COMIRNATY, formulation: solution for injection, Lot number: unknown) via unknown route of administration on unknown date as Dose 1,Single for COVID-19 immunization. He reported no issues when receiving the first dose. He also stated that under his physician's guidance he is scheduled for an EKG test. Shortly thereafter receiving second dose he developed pain in his left arm, predominately in his shoulder and the left side of chest. He also reported that the pain diminished after several days and then returned, and this cycle has occurred several times since receiving his 2nd dose. At the time of this report the outcome of the events were unknown.  No follow-up attempts were possible; information about lot/batch number cannot been obtained.
My arm started hurting a few weeks after the shot, not to the touch or where the injection was but when I lift it high or try to throw with it
Fever; nausea; vomiting; chills; body aches; This is a spontaneous report from a contactable nurse (patient) reported that a 29-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on an unspecified date then received the second dose on the left arm on 11Jan2021 08:00 both via an unspecified route of administration at a single dose for Covid-19 immunization. The patient medical history was reported as none. The patient takes multivitamins. On 11Jan2021 19:00, the patient experienced fever, nausea, vomiting, chills and body aches. The patient did not received any treatment for all the reported events. The outcome of the events was not recovered.   Information on the lot/batch number has been requested.
This spontaneous report was received from a licensed vocational nurse and refers to multiple unspecified patients of unknown age and gender. The patients' pertinent medical history, drug reactions or allergies and concomitant therapies were not reported. On unknown dates, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB (exact dose, route, lot # and expiration date were not reported). The administered doses experienced a temperature excursion of 34.7 degrees Fahrenheit for 2 hours. There was no previous temperature excursion. The stored vaccines were back in proper temperature range. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
I had typical symptoms, slamming headache, runny nose, sore throat and slight fever. I took a home test which was positive. The next day my chest was tight. My doctor prescribed Paxlovid for 5 days. I felt awful for 5 days, chest discomfort and tightness in my chest. I was having extreme difficulty breathing. My pulse ox dropped to 80%. One hour later the levels went back to normal. I continued to isolate for 5 more days. Day 9 I felt worse. Again, had a slight headache, hoarseness and sore throat, runny nose. I thought it was allergies. I started feeling worse on day 10. I was able to get a virtual appointment today. I am still testing positive today and not feeling well still. Albuterol inhaler was prescribed and another dose of Paxlovid.
I representative gave wrong dosage to patient. Patient recieved a mooderna booster(.25)instead of a full dosage(.5)Patient had no reaction to vaccine that she recieved.
Inappropriate schedule of vaccine administered; Rash developed on the arm where the injection was received; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207), via an unspecified route of administration in the left arm on 26Mar2021 at 12:30 (at the age of 41-year-old), as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. The patient had received other medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202), via an unspecified route of administration in the left arm on 15Mar2021 at 12:30 (at the age of 41-year-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 04Apr2021 at 14:00, i.e., 8 days after injection the patient experienced rash developed on the arm where the injection was received. The patient had no known allergies. The adverse events did not result in doctor/other health care professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event rash developed on the arm where the injection was received was not recovered.  No follow-up attempts are needed. No further information is expected.
Initial report received from a healthcare professional on 23 July 2013. A 06-month-old female patient had received an intramuscular third dose of DAPTACEL (batch number: C4050AB) in left thigh on 13 July 2012. The patient's medical history included minor food allergies and dry skin patches and had no illness at the time of vaccination. Concomitant medication was not reported. On 16 July 2013, 3 days after vaccination, the patient changed how she was babbling. She was no longer using consonants, only vowels. Otherwise no side effects. It seemed that the patient was frustrated when trying to babble. The patient had reduced amount of babbling. Corrective treatments and laboratory investigations were not reported. At the time of this report, the patient had not recovered from the events. Documents held by sender: none. Follow-up information received from a healthcare professional on 10 September 2013: The patient was not taking any concomitant medications. The patient birth weight was reported as 5 lb and 11 oz and the patient had no siblings. It was reported that patient was babbling interactively prior to vaccination; however after vaccination the babbling had stopped and the patient acted frustrated trying to babble. The babbling had resumed on 12 August 2013 and baby had recovered completely and was back to normal and doing well developmentally.
pt recv vax & devel a fever & mom gave motrin;4/7/98 pt temp was 103 in ear;mom then contacted MD who stated that motrin was not a good choice recommended APAP;T100
Extreme fatigue, Chills, Sweating beginning approximately 24 hrs. after vaccination and lasting approximately 36 hours.
1/27/2021 developed increased fatigue, required increased assistance with ADLs.  Continued with functional decline and overall decline in mentation.  Has impacted functional level (requiring increased assistance with feeding, bathing, dressing, toileting) and speech/swallow ability.  Decreased ability to respond/converse with staff